TECX — Tectonic Therapeutic Income Statement
0.000.00%
- $243.12m
- $152.64m
- 60
- 81
- 68
- 79
Annual income statement for Tectonic Therapeutic, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 75.8 | 120 | 119 | 105 | -11.1 |
Operating Profit | -75.8 | -120 | -119 | -105 | 11.1 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -73 | -120 | -119 | -106 | 12.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | -73 | -120 | -119 | -106 | 12.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -73 | -120 | -119 | -106 | 12.2 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -73 | -120 | -119 | -106 | 12.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -31.9 | -39.7 | -33.4 | -29.1 | -11.2 |